Altruist Biologics’ Suzhou Site Receives EMA GMP Certification

The company’s Quality Risk Management framework enabled proactive identification of compliance risks, reduced uncertainties associated with cross-regional technology transfer, and provided greater predictability as therapies advance toward regulatory submission and commercialization.

The post Altruist Biologics’ Suzhou Site Receives EMA GMP Certification appeared first on GEN - Genetic Engineering and Biotechnology News.